Teladoc Health, Inc.
NYSE:TDOCMedical - Healthcare Information Services
+$0.20 today
- Market cap
- $1.47B
- Beta
- 2.14
- P/E (TTM)
- -8.1
- EPS (TTM)
- -$0.96
Volume 3.96M
Average 4.68M
TDOC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Teladoc Health, Inc.NYSE: TDOC
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $67.87M fell 3.0% year over year, behind the +4.5% change in trailing-twelve-month research & development. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.
Context
- Research & development amounted to 11.0% of revenue in FY2025, down 1.0 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.0% toward the trailing-twelve-month pace of +4.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 277.92M USD
- Year-over-year change
- -9.6%
- 4-year CAGR
- -2.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 277.92M | -9.6% |
| FY2024 | 2024-12-31 | 307.27M | -11.8% |
| FY2023 | 2023-12-31 | 348.52M | +4.5% |
| FY2022 | 2022-12-31 | 333.63M | +7.0% |
| FY2021 | 2021-12-31 | 311.88M | — |
Research & Development vs competitors
How TDOC compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +4.5% is the 5th highest of 10, against a peer median of +1.0%.
- Research & development amounts to 12.7% of revenue for TDOC, versus a peer median of 9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $320.12M USD | +4.5% | -5.9% | 12.7% | |
| LTM Sep 2026 | $236.54M USD | +35.6% | +95.7% | — | |
| LTM Mar 2026 | $229.1M USD | +8.2% | +2.9% | 34.0% | |
| LTM Sep 2026 | $160.31M USD | -11.5% | +11.1% | 59.6% | |
| LTM Sep 2026 | €132.22M EUR | +7.0% | +29.5% | — | |
| LTM Apr 2026 | $117.98M USD | -1.9% | +10.0% | 23.8% | |
| LTM Mar 2026 | $89.67M USD | +1.0% | -5.8% | 7.3% | |
| LTM Sep 2026 | $37.92M USD | +31.1% | +3.7% | 6.1% | |
| LTM Mar 2026 | €36.91M EUR | -18.7% | -1.0% | 5.0% | |
| LTM Mar 2026 | $32.6M USD | -8.9% | +15.8% | 11.5% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding TDOC) | — | +1.0% | +10.0% | 9.4% | |
Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.03B | 2.41B | 2.6B | 2.57B | 2.53B |
| Cost of Revenue | 650.26M | 743.99M | 760.03M | 751.27M | 771.59M |
| Gross Profit | 1.38B | 1.66B | 1.84B | 1.82B | 1.76B |
| Gross Margin | 68.0% | 69.1% | 70.8% | 70.8% | 69.5% |
| Research & Development | 311.88M | 333.63M | 348.52M | 307.27M | 277.92M |
| Selling, General & Admin | 1.11B | 1.3B | 1.37B | 1.35B | 1.09B |
| Operating Expenses | 1.65B | 15.32B | 2.09B | 2.84B | 2.02B |
| Depreciation & Amortization | 207.57M | 209.93M | 254.11M | 240.51M | 363.12M |
| EBITDA | (31.42M) | (7.54M) | 43.61M | 31.72M | 147.3M |
| EBITDA Margin | -1.5% | -0.3% | 1.7% | 1.2% | 5.8% |
| Operating Income | (265.63M) | (13.65B) | (248.55M) | (1.02B) | (262.96M) |
| Operating Margin | -13.1% | -567.3% | -9.6% | -39.7% | -10.4% |
| Interest Income | 776K | 12.67M | 46.78M | 57.07M | 36.77M |
| Interest Expense | 81.14M | 21.94M | 22.28M | 23.8M | 19.71M |
| Other Income / Expenses | (119.03M) | (10.13M) | 28.95M | 27.23M | 27.43M |
| Income Before Tax | (384.66M) | (13.66B) | (219.61M) | (993.65M) | (235.53M) |
| Pre-Tax Margin | -18.9% | -567.7% | -8.4% | -38.7% | -9.3% |
| Income Tax Expense | 44.14M | (3.81M) | 760K | 7.59M | (35.21M) |
| Net Income | (428.79M) | (13.66B) | (220.37M) | (1B) | (200.32M) |
| Net Margin | -21.1% | -567.5% | -8.5% | -39.0% | -7.9% |
| EPS (Basic) | (2.73) | (84.60) | (1.36) | (5.87) | (1.14) |
| EPS (Diluted) | (2.73) | (84.60) | (1.34) | (5.87) | (1.14) |
| Weighted Avg Shares | 156.94M | 161.46M | 162.17M | 170.56M | 176.22M |
| Weighted Avg Shares (Diluted) | 156.94M | 161.46M | 164.58M | 170.56M | 176.22M |
Teladoc Health, Inc.
NYSE:TDOC
Intrinsic Alpha fair value
Locked
Current Price
$8.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.